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Abstract: We studied the effects of audible and visual alarms on adherence with a recommended 
dosing regimen in the management of glaucoma. Forty-two patients were begun on therapy with 
the Travatan® Dosing Aid (TDA) and randomly divided into two observation groups – one with 
visual and audible alarm functions turned on and the other with alarms off. Dosing information 
was analyzed for mean rates of adherence, missed days, and dosing at the wrong time. Twenty 
patients were randomized to the TDA alarm on group and 22 to the alarm off group. The rates 
of adherence were 87.9% and 79.7% (p = 0.02), rates of missed dosing were 7.6% and 14.4% 
(p = 0.03), and rates of dosing at the incorrect times were 7.1% and 9.8% (p = 0.19), respectively 
for alarm on versus alarm off groups. In the alarm on group, the adherence rate was signiﬁ  cantly 
higher and proportion of missed dosing was signiﬁ  cantly lower. It is still yet to be determined 
whether there is a relationship between adherence and progression of glaucoma.
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Introduction
Glaucoma is the second leading cause of blindness in the world according to the World 
Health Organization (Glaucoma Research Foundation). While there are multiple 
treatments for glaucoma, medical therapy is still the mainstay of therapy, especially 
in the early phases of the disease. Given the chronic and initially asymptomatic nature 
of this condition, adherence to prescribed treatment regimens is a signiﬁ  cant problem 
for patients (Jackevicius et al 2002; Cramer et al 2003; Sewitch et al 2003; Osterberg 
and Blaschke 2005). Lack of consistency with dosing can lead to persistent elevation 
or ﬂ  uctuations of intraocular pressure (IOP), which has been shown to be a risk factor 
for glaucomatous progression (Nouri-Mahdavi et al 2004). Therefore, improving 
patients’ adherence to therapy is of the utmost importance.
There are many reasons for patients to be non-adherent to their treatment regimens 
(Patel and Spaeth 1995). Some of these include cost of medications, inability to dose 
the medications themselves, side effects, and failure to understand the role of medical 
therapy in the treatment of their disease. However, the most commonly cited reason 
for not dosing is patient forgetfulness (Patel and Spaeth 1995; Taylor et al 2002). An 
electronic medication-monitoring device, coupled with a reminder mechanism, allows 
physicians to indirectly measure adherence and may also decrease patient forgetfulness. 
However, the behavioral effects of these reminders, independent of other factors such 
as the intervention and measuring patient behavior, are yet to be determined.
Electronic monitoring is currently viewed as the most objective measure of a patient’s 
adherence to a prescribed medical regimen (Farmer 1999). The date and time stamping 
mechanisms for the Travatan® Dosing Aid (TDA) (Alcon, Fort Worth, TX, USA) Clinical Ophthalmology 2008:2(4) 770
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we used in this study has been shown to be both accurate and 
reproducible (Boden et al 2006; Cronin et al 2007). In this 
study, we examined how audible and visual alarms on a com-
mercially available glaucoma medication dosing aid affected 
adherence to a monotherapy eyedrop dosing regimen.
Methods
Forty-two individuals newly diagnosed with glaucoma 
were studied. Eligibility criteria included any patient who 
presented to the glaucoma service between January 1, 2006 
and January 1, 2007 who had never used topical glaucoma 
medications before and were willing to participate in the study. 
They were placed on monotherapy with travoprost (Travatan®, 
Alcon, Fort Worth, TX). The basic design of the device has 
been previously described (Boden et al 2006). The TDA has 
an LCD screen that displays a ﬂ  ashing eye drop symbol on the 
front as a visible reminder when a patient is supposed to give 
themselves a dose of medication and it also emits an audible 
beep as an audible reminder. The patients were randomly 
assigned to begin once-daily dosing with this medication 
placed in the TDA with the alarm functions on or turned off.
Prior to use, the patient’s name, demographic information, 
and prescribed dosing time were programmed into the device. 
In those cases in which the reminders were not used, the screen 
on the front of the TDA was covered with black tape and the 
audible alarm was turned off. In both situations, the device 
electronically monitored eye drop administration dates, times, 
and the number of drops administered (Figure 1).
Each patient was then given detailed instructions on the 
proper usage of the device. The dosing information was then 
downloaded from the TDA at the follow up visits 3–5 weeks 
later using the specialized cradle connected to a PC and a 
customized print out was obtained. Taking the medication 
outside the designated time frame was also noted as a 
nonadherence event and marked with a star on the printout 
(Figure 1). We analyzed the information for rates of adher-
ence, missed dosing, dosing at the wrong time, double dosing, 
and range of time over which the drops were administered 
throughout the observation period.
In this study, adherence was deﬁ  ned as the number of 
days on which a drop was administered within 3 hours of 
the scheduled dose time regardless of whether or not one or 
more doses were administered that day. Non-adherence was 
deﬁ  ned as the number of days where no drop was adminis-
tered at all or if no drops that day were administered within 
3 hours of the scheduled dosing time. Dosing at the incor-
rect time was deﬁ  ned as administration of a drop outside the 
3-hour window of the scheduled dose time. Comparisons 
were then made between the two groups using the non-
parametric Kruskal-Wallis t-test and summary statistics.
Results
Of the 42 patients in our study, 23 were female and 19 were 
male. The age range was 42–91 years (mean, 69.1 ± SD 12.5). 
Twenty patients were randomly assigned to the TDA alarm 
on group and 22 to the alarm off group. In the alarm on group, 
the observation period was 9–84 days and the mean duration 
of observation was 37.6 ± 18.1 days. In the alarm off group, 
the observation period was 6–63 days and the mean duration 
of observation was 35.4 ± 16.2 days (p = 0.28).
The adherence rates (Figure 2) were 87.9% and 79.7% 
(p = 0.02), rates of missed dosing (Figure 3) were 7.6% and 
14.4% (p = 0.03), and rates of dosing at the incorrect times 
(Figure 4) were 7.1% and 9.8% (p = 0.19), respectively for 
alarm on versus alarm off groups. The mean range of time 
between dose administration and scheduled dose time was 
207 ± 108 minutes for the alarm on group and 424 ± 405 
minutes for the alarm off group (p = 0.08).
Discussion
In a recent evidence-based literature review of non-compliance 
with ocular hypotensive treatments, the proportion of patients 
who deviated from their prescribed medication regimen 
ranged from 5% to 80% with several different measurements 
of compliance (Olthoff et al 2005). Compliance is classically 
deﬁ  ned as the extent to which patients’ behaviors correspond 
with providers’ recommendations (Schwartz 2005). We prefer 
the term adherence to therapy because it implies a more active 
patient participation and is more reﬂ  ective of how medicine 
is practiced today.
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Figure 1 The dosing aid printout is divided into 3 columns that include date, time, 
and number of lever depressions. In this case the star to the left of the date denotes 
non-adherence to a programmed regimen. The absence of a star means the patient 
was adherent on that date.Clinical Ophthalmology 2008:2(4) 771
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Methods for measuring adherence to glaucoma medications 
have included but are not limited to patient interviewing, 
questionnaires or self reporting, biomarkers, prescription 
reﬁ  ll rate, and electronic medication monitoring systems 
or combinations of the above (Kass et al 1986; Patel 
and Spaeth 1995; Tsai et al 2003; Nordstrom et al 2005; 
Boden et al 2006; Sleath et al 2006). The deﬁ  nition of 
adherence/compliance also varies across studies without 
any standardization. 
In the present study, there were trends toward fewer days 
of dosing at incorrect times and a smaller average range of 
time between drop administration and scheduled dose time 
in the reminder group but these differences were not statisti-
cally signiﬁ  cant. Some explanations for this lack of observed 
difference could be could be a relatively small sample size, 
short follow-up time, a biased population in that the patients 
had not used topical glaucoma therapy previously, and other 
factors such as new side effects may have come into play. 
Also, we did not randomize for situational/environmental 
factors (depression, race, marital status, children in house-
hold), medication regimens (the use of other systemic medica-
tions, medication side effects), patient related factors (general 
health, mentation, comprehension, vision, disability, health 
literacy), or provider related factors (duration of follow up), 
all of which have all been associated with lack of medication 
adherence (Tsai et al 2003; Tsai 2006). Another possible 
reason for the non-statistical signiﬁ  cance is that when the 
patients are in a study they tend to be more compliant to their 
therapy (Lievens et al 2006).
The difference in the adherence rate and rate of missed 
doses was statistically signiﬁ  cant between the two groups 
in our study. This suggests that the presence of the audible 
and visible alarms improved adherence and decreased the 
likelihood of missing a dose. Even if the patient was a 
sporadic user or did forget to dose at the appropriate time 
initially, the reminders may have rescued that day’s dosing 
on some days.
The adherence rate for the reminder group was slightly 
higher than published overall rates of adherence but a recent 
study of adherence with the same monitoring device yielded 
similar rates of adherence (Kahook and Noecker 2007). 
Our rates may have been higher secondary to our sample 
size and our deﬁ  nition of adherence. We considered those 
patients who double dosed or dosed at the incorrect time to 
be adherent if they still administered one drop within 3 hours 
of scheduled time period. It is also impossible to assess 
whether or not the drop actually landed on the eye after a 
patient knowingly administered a drop. Another question not 
answered in our study was that the difference in reminder 
capability between audible and visual reminders. We did 
not separate the visual alarm from the audible alarm in order 
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Figure 2 Mean adherence rate for those dosing travoprost with the alarm on 87.9% 
compared with alarm off 79.7% was statistically signiﬁ  cant (p = 0.02).
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Figure 3 Mean rate of missed dosing for those on travoprost with the alarm on 7.6% 
compared with the alarm off 14.4% was statistically signiﬁ  cant (p = 0.03).
Figure 4 Mean rate for those dosing travoprost at the incorrect times with the alarm 
on 7.1% compared with the alarm off 9.8% was not statistically signiﬁ  cant (p = 0.19).
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
M
e
a
n
 
%
 
o
f
 
d
o
s
i
n
g
 
a
t
 
i
n
c
o
r
r
e
c
t
 
t
i
m
e
Alarm On
Alarm OffClinical Ophthalmology 2008:2(4) 772
Ho et al
to see if one or the other was more effective on individual 
adherence rates. Nonetheless, the dosing device appeared 
to provide a reasonably accurate and objective method of 
recording adherence in these patients.
Conclusion
Monitoring of patient dosing behavior remains an elusive but 
attractive component of therapy for glaucoma. Being able 
to accurately determine the effect of patient adherence on 
therapy can be a powerful tool in determining which therapy 
works the best for a given individual. The effectiveness of 
reminders, as they currently exist, remains unclear but did 
appear to result in higher adherence rates and a diminished 
rate of missed dosing in this glaucoma population. It is still 
yet to be determined whether there is a relationship between 
adherence and progression of glaucoma. Larger prospective 
studies are needed to further elucidate the effect of visual and 
audible cues and their inﬂ  uence on adherence to glaucoma 
treatment regimens.
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